{"url_path":"/sec/bglc/8-k/2026-06-05/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-05","source_url":"https://www.sec.gov/Archives/edgar/data/1737523/0001477932-26-003658-index.html","accession_number":"0001477932-26-003658","cik":"0001737523","ticker":"BGLC","issuer_name":"BioNexus Gene Lab Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1737523/0001477932-26-003658-index.html","primary_entity_key":"0001737523","primary_entity_name":"BioNexus Gene Lab Corp"},"word_count":298,"has_tables":true,"body_markdown":"bglc_8k.htm\n0001737523false00017375232026-05-292026-05-29iso4217:USDxbrli:sharesiso4217:USDxbrli:shares\n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 8-K**\n\n \n\n**CURRENT REPORT**\n\n**PURSUANT TO SECTION 13 OR 15(d) OF**\n\n**THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\nDate of Report (Date of earliest event reported): **May 29, 2026**\n\n \n\n**BioNexus Gene Lab Corp.**\n\n(Exact name of Company as specified in its charter)\n\n \n\n**Wyoming**\n\n \n\n**001-41750**\n\n \n\n**35-2604830**\n\n(State or other jurisdiction\n\n \n\n(Commission\n\n \n\n(IRS Employer\n\nof Incorporation)\n\n \n\nFile Number)\n\n \n\nIdentification Number)\n\n \n\n**Unit A-28-7, Tower A, Menara UOA Bangsar,**\n\n**No.5 Jln Bangsar Utama 1,**\n\n**59000 Kuala Lumpur, Malaysia**\n\n(Address of principal executive offices)\n\n \n\n**Phone: +1 (307) 241-6898**\n\n(Company’s Telephone Number)\n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:\n\n \n\n☐\n\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n \n\n☐\n\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n \n\n☐\n\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n \n\n☐\n\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\n**Title of each class**\n\n \n\n**Trading Symbol(s)**\n\n \n\n**Name of each exchange on which registered**\n\nCommon Stock, no par value\n\n \n\nBGLC\n\n \n\nThe Nasdaq Stock Market LLC\n\n \n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging growth company ☒\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐"}